CANbridge Life Sciences elects two key executives
8 May 2018 -

Biopharmaceutical company CANbridge Life Sciences announced on Monday the appointment of Annie Teng, MD as the new VP of its Clinical Development and Medical Affairs.

In addition, the company has named Janny Wang as the new director of its Quality Assurance.

Most recently, Dr Teng has served as medical director, Specialty Care, as well as head of Biology & Early Development at Sanofi, respectively.

Previously, Dr Teng was employed as disease area head for Oncology and Immunology at Bristol-Meyer-Squibb China, worked in oncology at Pfizer & Pharmacia (later acquired by Pfizer) as well as started her medical career in pediatrics at Chinese PLA Hospital.

Recently, Wang worked for 11 years with Teva Pharmaceutical Industry subsidiary, Teva Pharmaceutical & Chemical, in China, including quality assurance and quality control associate director as well as quality control manager at the Bayer Pharmaceuticals subsidiary, Dihon Pharmaceutical Group, in China.